Winnoz Technology, Inc. | May 3, 2023
Transforming Molecular Detection with Winnoz's IVD-Class Molecular Point-of-Care Technology
"Winnoz seeks strategic partnerships with testing kit manufacturers for eGGi Molecular Detection System and blood testing service providers for Haiim Blood Collection System at 2023 AACC."
The current healthcare ecosystem faces numerous challenges, including inadequate medical capacity, rising healthcare costs, aging population, healthcare worker burnout, and resource allocation crises. According to an article published by McKinsey & Company in 2022, it is estimated that by 2025, up to $265 billion of healthcare services will transition from traditional care models to decentralized telemedicine models such as mobile care and home care. Winnoz Technology is a biotech company that specializes in decentralized healthcare and biosensing technology. Our vision is to enable preventive screening for anyone, anywhere. Through our decentralized point-of-care platform, which involves blood sampling and molecular detection, we aim to provide customers with more efficient and affordable health management services.
In line with our proactive strategy to explore international markets and establish a global presence, Winnoz Technology will be participating in various domestic and international trade shows and events this year. This includes our participation in AACC 2023, which will take place in July at the Anaheim Convention Center.
"We are eagerly looking forward to this year's international market expansion plans," said Dr. Joses Hsiung, CEO of Winnoz. "At AACC, we hope to connect with more like-minded enterprises that share our vision and are actively pursuing the global market. We are seeking strategic partners who provide blood testing services, develop and manufacture testing reagents, and focus on decentralized healthcare services."
eGGi Satisfies the Need for Point-of-Care Testing
The eGGi molecular detection system is a powerful tool for identifying pathogens in animals, humans, and other specific targets. Its isothermal amplification technology can amplify targeting regions of a gene from a few copies to trillions in just a few minutes, making it a highly accurate and efficient testing solution for faster and more affordable molecular diagnostics testing at the point of care. The system is also open and compatible with a wide range of testing kits, allowing customization to meet your specific testing needs of a molecular detection analyzer from hardware to software.
We are actively seeking strategic partnerships with testing kit manufacturers to expand the use of this technology in the healthcare industry. Interested parties are encouraged to visit Winnoz's booth at the exhibitions or contact the company directly to learn more about this exciting new product and partnership opportunities.
Media contact: Verisia Lin | verisial@winnoz.com | 0973-034917
Winnoz website: https://winnoz.com